{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:20:21Z","timestamp":1780482021854,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006384","name":"American College of Radiology Imaging Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["Z99 CA999999"],"award-info":[{"award-number":["Z99 CA999999"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006686","name":"University of Miami","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijrobp.2025.01.008","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T20:37:09Z","timestamp":1737578229000},"page":"1192-1201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic \u201cMicroboost\u201d"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2120-1939","authenticated-orcid":false,"given":"Krishnan R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Dal","family":"Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich P.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah E.","family":"Citrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Ryckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.01.008_bib0001","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0360-3016(88)90224-6","article-title":"The effect of dose on local control of prostate cancer","volume":"15","author":"Hanks","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0002","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0360-3016(86)90059-3","article-title":"Tumor control in definitive irradiation of localized carcinoma of the prostate","volume":"12","author":"Perez","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0004","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0007","doi-asserted-by":"crossref","first-page":"LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","article-title":"Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/radiology.209.1.9769828","article-title":"Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy \u2013 a dose-escalation study","volume":"209","author":"Zelefsky","year":"1998","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer\u2014Results from a multi-institutional clinical trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","article-title":"Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer","volume":"89","author":"Kim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0011","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal Boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the flame randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0012","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","article-title":"Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer","volume":"82","author":"Groen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2021.06.033","article-title":"Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"162","author":"Groen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0016","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.2022.40.6_suppl.255","article-title":"Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): interim analysis of a phase III randomized trial","volume":"40","author":"Kishan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0017","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The well-built clinical question: a key to evidence-based decisions","volume":"123","author":"Richardson","year":"1995","journal-title":"ACP J Club"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0018","first-page":"359","article-title":"Evaluation of PICO as a knowledge representation for clinical questions","volume":"2006","author":"Huang","year":"2006","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3122\/jabfm.12.3.225","article-title":"Information at the point of care: answering clinical questions","volume":"12","author":"Ebell","year":"1999","journal-title":"J Am Board Fam Pract"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0020","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0022","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0024","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1118\/1.3246613","article-title":"AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of task group 137","volume":"36","author":"Nath","year":"2009","journal-title":"Med Phy"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0026","article-title":"Treatment for prostate cancer: external-beam radiation therapy","author":"Worthington","year":"2022","journal-title":"prostate cnacer foundation"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0027","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0028","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.prro.2024.06.006","article-title":"Target volume optimization for localized prostate cancer","volume":"14","author":"Patel","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0029","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2024.42.4_suppl.298","article-title":"Microboost dose escalation for localized prostate cancer within a statewide radiation oncology quality consortium","volume":"42","author":"Regan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0030","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1016\/j.ijrobp.2023.06.1643","article-title":"Use of focal radiotherapy boost for prostate cancer and perceived barriers toward its implementation: a survey","volume":"117","author":"Zhong","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0031","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","article-title":"Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial","volume":"127","author":"Monninkhof","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0032","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0033","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0034","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2024.02.027","article-title":"In regard to Ong et al","volume":"119","author":"Onal","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0035","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/modpathol.3800431","article-title":"Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens","volume":"18","author":"Cheng","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0036","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/j.ijrobp.2022.07.1206","article-title":"Dose to the bladder trigone and acute urinary toxicity after prostate SBRT in a randomized phase 3 trial","volume":"114","author":"Patel","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0037","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","article-title":"Genitourinary \u03b1\/\u03b2 ratios in the CHHiP Trial the fraction size sensitivity of late genitourinary toxicity: analysis of alpha\/beta (\u03b1\/\u03b2) ratios in the CHHiP trial","volume":"115","author":"Brand","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0038","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1748-717X-7-82","article-title":"Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy","volume":"7","author":"Vainshtein","year":"2012","journal-title":"Radiation Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0039","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate stereotactic body radiation therapy: an overview of toxicity and dose response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0041","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.clon.2018.05.001","article-title":"An investigation of dosimetric correlates of acute toxicity in prostate stereotactic body radiotherapy: dose to urinary trigone is associated with acute urinary toxicity","volume":"30","author":"Henderson","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0042","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2023.07.044","article-title":"Risk Modeling for Individualization of the FLAME focal boost approach in external beam radiation therapy for patients with localized prostate cancer","volume":"118","author":"Guricov\u00e1","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0043","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pros.22903","article-title":"Biologic differences between peripheral and transition zone prostate cancer","volume":"75","author":"Lee","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.ijrobp.2025.01.008_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jicru_ndq002","article-title":"Report 83: prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT)","volume":"10","author":"Gregoire","year":"2010","journal-title":"J ICRU"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:50:41Z","timestamp":1762296641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0360301625000549"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.008","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic \u201cMicroboost\u201d","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}